Quarterly ResultAug 13, 2026, 04:09 PM
MDxHealth Q2 Revenue +16% to $27.2M; Operating Loss $5.1M
AI Summary
MDxHealth reported Q2 2026 financial results with revenue increasing 16% year-over-year to $27.2 million, driven by sequential growth and integration of the ExoDx business. However, the company experienced increased operating and net losses, and adjusted EBITDA turned negative, primarily due to higher operating expenses from the ExoDx acquisition. MDxHealth successfully completed the wind-down of its Resolve mdx business and secured $20 million in gross proceeds from a registered direct placement to institutional investors, strengthening its balance sheet and supporting future growth initiatives.
Key Highlights
- Q2 2026 revenue increased 16% to $27.2 million.
- Q2 2026 operating loss was $5.1 million, up from $1.5 million in Q2 2025.
- Q2 2026 net loss was $9.5 million, up from $7.0 million in Q2 2025.
- Q2 2026 adjusted EBITDA was ($2.3) million, compared to $1.1 million in Q2 2025.
- Tissue-based test volume decreased 1% YoY but increased 13% sequentially to 12,525.
- Liquid-based test volume was 13,578, compared to 4,455 Select mdx volume in Q2 2025.
- Cash and cash equivalents stood at $19.2 million as of June 30, 2026.
- Completed a registered direct placement raising $20 million in gross proceeds.
Price Impact
More from MDXH